Discovery of a highly potent and orally available importin-<i>β</i>1 inhibitor that overcomes enzalutamide-resistance in advanced prostate cancer.

Authors:
Huang JL; Yan XL; Huang D; Gan L; Gao H and 8 more

Journal:
Acta Pharm Sin B

Publication Year: 2023

DOI:
10.1016/j.apsb.2023.07.017

PMCID:
PMC10692375

PMID:
38045040

Journal Information

Full Title: Acta Pharm Sin B

Abbreviation: Acta Pharm Sin B

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Pharmacology & Pharmacy

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Conflicts of interest The authors declare no conflicts of interest."

Evidence found in paper:

"This work was supported by the Natural Science Foundation of China (Nos. 82273804, 81973195, 81872891, and 81973203), the Southern Marine Science and Engineering Guangdong Laboratory (Zhuhai) (No. SML2021SP301, China), Open Program of Shenzhen Bay Laboratory (No. SZBL2021080601007, China), the Guangdong Natural Science Funds for Distinguished Young Scholar (No. 2019B151502016, China), Guangdong-Hong Kong-Macao research team project of the Guangdong Basic and Applied Basic Research Foundation (No. 2022B1515130008, China)."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025